The cursed duet today: Tuberculosis and HIV-coinfection

Presse Med. 2017 Mar;46(2 Pt 2):e23-e39. doi: 10.1016/j.lpm.2017.01.017. Epub 2017 Feb 28.


The tuberculosis (TB) and HIV syndemic continues to rage and are a major public health concern worldwide. This deadly association raises complexity and represent a significant barrier towards TB elimination. TB continues to be the leading cause of death amongst HIV-infected people. This paper reports the challenges that lay ahead and outlines some of the current and future strategies that may be able to address this co-epidemic efficiently. Improved diagnostics, cheaper and more effective drugs, shorter treatment regimens for both drug-sensitive and drug-resistant TB are discussed. Also, special topics on drug interactions, TB-IRIS and TB relapse are also described. Notwithstanding the defeats and meagre investments, diagnosis and management of the two diseases have seen significant and unexpected improvements of late. On the HIV side, expansion of ART coverage, development of new updated guidelines aimed at the universal treatment of those infected, and the increasing availability of newer, more efficacious and less toxic drugs are an essential element to controlling the two epidemics. On the TB side, diagnosis of MDR-TB is becoming easier and faster thanks to the new PCR-based technologies, new anti-TB drugs active against both sensitive and resistant strains (i.e. bedaquiline and delamanid) have been developed and a few more are in the pipeline, new regimens (cheaper, shorter and/or more effective) have been introduced (such as the "Bangladesh regimen") or are being tested for MDR-TB and drug-sensitive-TB. However, still more resources will be required to implement an integrated approach, install new diagnostic tests, and develop simpler and shorter treatment regimens.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / therapeutic use
  • Antitubercular Agents / pharmacokinetics
  • Antitubercular Agents / therapeutic use
  • Bacteriological Techniques
  • Clinical Trials as Topic
  • Comorbidity
  • Disease Management
  • Disease Reservoirs
  • Drug Interactions
  • Drug Resistance, Multiple, Bacterial
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology*
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / physiopathology
  • Immune Reconstitution Inflammatory Syndrome / therapy
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy
  • Mass Screening / methods
  • Mycobacterium tuberculosis / drug effects
  • Tuberculosis / diagnosis
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology*
  • Tuberculosis / prevention & control
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology


  • Anti-HIV Agents
  • Antitubercular Agents